Plus Therapeutics Partners with Ephemeral Technologies to Deploy AI Execution Platform for CNS Oncology

Plus Therapeutics has entered a strategic partnership with Ephemeral Technologies to create an AI execution platform aimed at unifying and analyzing data related to CNS oncology. This collaboration seeks to enhance the efficiency of laboratory and clinical workflows, improve patient outcomes, and further establish Plus as a leader in treating central nervous system cancers. The platform will integrate various datasets from Plus’ therapeutic and diagnostic efforts to support precision oncology and operational decision-making.